Revvity / Oxford Immunotec

Oxford Immunotec is now Revvity. Our products and services are now part of Revvity's portfolio.

Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company was founded in 2002 based on world-leading research at the University of Oxford. The European headquarters are located in Abingdon, UK and the North American headquarters are located in Marlborough, MA USA.

The company's first product is the T-SPOT.TB test, a cellular blood test for the detection of active and latent TB infection. The test was CE marked in Europe in July 2004, licensed in Canada in 2005 and was FDA approved in the United States in July of 2008.

At Revvity, “impossible” is inspiration, and ""can't be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

RESEARCH & DEVELOPMENT
Genomic Analysis
Protein Analysis
Cell Analysis
Research Solutions

SIGNALS SOFTWARE

CLINICAL & DIAGNOSTICS
Reproductive Health
Infectious Diseases
Autoimmunity
Endocrinology
Allergy
Cancer
Neurodegeneration
Rapid Patient Testing

PLATFORMS & AUTOMATION
Sample Prep
Automated Liquid Handlers
Integrated Laboratory Automation
Detection
Imaging
In Vitro Diagnostics (IVD) Platforms & Automation

ADVANCED SERVICES & LICENSING
Pharma Services
Licensing
Clinical Services
OEM Solutions